SG11201606054SA - Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use - Google Patents

Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Info

Publication number: SG11201606054SA
Authority: SG; Singapore
Prior art keywords: methylcyclohexylamino; butylamino; carboxamide; pyrimidine; tert
Prior art date: 2014-01-30

Application number

SG11201606054SA

Other languages

English (en)

Inventor

Antonio Christian Ferretti

Hon-Wah Man

Jale Muslehiddinoglu

Jean Xu

Kelvin Hin-Yeong Yong

Marie Georges Beauchamps

Mohit Atul Kothare

Nanfei Zhou

Nathan Andrew Boersen

Ying Li

Robert Hilgraf

Mark A Nagy

Daozhong Zou

Lianfeng Huang

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-30

Filing date

2015-01-29

Publication date

2016-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606054S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-29 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2016-08-30 Publication of SG11201606054SA publication Critical patent/SG11201606054SA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Cosmetics (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11201606054SA 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use SG11201606054SA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461933636P	2014-01-30	2014-01-30
US201462025161P	2014-07-16	2014-07-16
PCT/US2015/013412 WO2015116755A2 (en)	2014-01-30	2015-01-29	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Publications (1)

Publication Number	Publication Date
SG11201606054SA true SG11201606054SA (en)	2016-08-30

Family

ID=53678405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201606054SA SG11201606054SA (en)	2014-01-30	2015-01-29	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Country Status (32)

Country	Link
US (7)	US9365524B2 (pt)
EP (2)	EP3738954A1 (pt)
JP (3)	JP2017504632A (pt)
KR (2)	KR102760889B1 (pt)
CN (3)	CN113717109A (pt)
AU (2)	AU2015211036B2 (pt)
BR (2)	BR122020003206B1 (pt)
CA (1)	CA2938187C (pt)
CL (1)	CL2016001927A1 (pt)
CR (1)	CR20160346A (pt)
CY (1)	CY1123267T1 (pt)
DK (1)	DK3099302T3 (pt)
EA (2)	EA031671B1 (pt)
ES (1)	ES2811834T3 (pt)
HR (1)	HRP20201244T1 (pt)
HU (1)	HUE051266T2 (pt)
IL (2)	IL246931B (pt)
LT (1)	LT3099302T (pt)
MX (3)	MX391127B (pt)
MY (1)	MY180020A (pt)
NZ (3)	NZ715903A (pt)
PE (1)	PE20161437A1 (pt)
PH (1)	PH12016501472B1 (pt)
PL (1)	PL3099302T3 (pt)
PT (1)	PT3099302T (pt)
RS (1)	RS60715B1 (pt)
SA (1)	SA516371578B1 (pt)
SG (1)	SG11201606054SA (pt)
SI (1)	SI3099302T1 (pt)
SM (1)	SMT202000430T1 (pt)
TW (1)	TWI631108B (pt)
WO (1)	WO2015116755A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111471021B (zh) *	2011-04-22	2024-04-02	西格诺药品有限公司	取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
NZ715903A (en) *	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CA2970926C (en) *	2014-12-16	2023-10-24	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3233808B1 (en)	2014-12-16	2021-07-14	Signal Pharmaceuticals, LLC	Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en)	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3325432B1 (en) *	2015-07-24	2020-09-02	Celgene Corporation	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (zh)	2019-05-13	2021-10-26	华为技术有限公司	天线装置及移动终端
CN113698408A (zh) *	2020-05-22	2021-11-26	武汉朗来科技发展有限公司	Jnk抑制剂、其药物组合物和用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH549339A (de)	1971-05-12	1974-05-31	Ciba Geigy Ag	Herbizides mittel.
US5811428A (en) *	1995-12-18	1998-09-22	Signal Pharmaceuticals, Inc.	Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5935966A (en) *	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) *	1995-12-18	1998-12-22	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
JP4135318B2 (ja)	1997-12-15	2008-08-20	アステラス製薬株式会社	新規なピリミジン−５−カルボキサミド誘導体
EP1107957B1 (en)	1998-08-29	2006-10-18	AstraZeneca AB	Pyrimidine compounds
WO2000075113A1 (fr)	1999-06-09	2000-12-14	Yamanouchi Pharmaceutical Co., Ltd.	Nouveaux derives carboxamide heterocycliques
WO2000076980A1 (fr)	1999-06-10	2000-12-21	Yamanouchi Pharmaceutical Co., Ltd.	Nouveaux derives heterocycliques azotes ou leurs sels
US7122544B2 (en) *	2000-12-06	2006-10-17	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) *	2000-12-06	2006-10-31	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) *	2000-12-06	2008-09-30	Signal Pharmaceuticals, Llc	Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
JPWO2003082855A1 (ja)	2002-03-28	2005-08-04	協和醗酵工業株式会社	抗炎症剤
JP4529685B2 (ja) *	2002-06-28	2010-08-25	アステラス製薬株式会社	ジアミノピリミジンカルボキサミド誘導体
JP2006514989A (ja)	2002-07-29	2006-05-18	ライジェルファーマシューティカルズ	２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
US20040185429A1 (en) *	2002-12-09	2004-09-23	Judith Kelleher-Andersson	Method for discovering neurogenic agents
WO2004054617A1 (ja)	2002-12-13	2004-07-01	Kyowa Hakko Kogyo Co., Ltd.	中枢疾患の予防および／または治療剤
EP1590334B1 (en)	2003-01-30	2009-08-19	Boehringer Ingelheim Pharmaceuticals Inc.	2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
DK2287156T3 (da)	2003-08-15	2013-08-26	Novartis Ag	2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
CA2539235A1 (en)	2003-09-24	2005-04-07	Wyeth Holdings Corporation	5-arylpyrimidines as anticancer agents
JPWO2005095382A1 (ja)	2004-03-30	2007-08-16	協和醗酵工業株式会社	抗腫瘍剤
US7601714B2 (en)	2004-07-08	2009-10-13	Boehringer Ingelheim Pharmaceuticals, Inc.	Pyrimidine derivatives useful as inhibitors of PKC-theta
JP2008512429A (ja)	2004-09-10	2008-04-24	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
WO2006027377A1 (en)	2004-09-10	2006-03-16	Altana Pharma Ag	Ciclesonide and syk inhibitor combination and methods of use thereof
JP2006124387A (ja)	2004-09-30	2006-05-18	Taisho Pharmaceut Co Ltd	新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
ATE542802T1 (de)	2004-09-30	2012-02-15	Tibotec Pharm Ltd	Hiv-inhibierende 5-substituierte pyrimidine
WO2006091737A1 (en)	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
US20110098301A1 (en)	2005-03-10	2011-04-28	Bayer Healthcare Llc	Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
DE102005062742A1 (de) *	2005-12-22	2007-06-28	Bayer Schering Pharma Ag	Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
KR20090031787A (ko)	2006-07-21	2009-03-27	노파르티스 아게	Ｊａｋ 키나제 억제제로서의 ２,４-디(아릴아미노)-피리미딘-５-카르복스아미드 화합물
US20080139531A1 (en)	2006-12-04	2008-06-12	Alcon Manufacturing Ltd.	Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
AP2009005010A0 (en)	2007-04-18	2009-10-31	Pfizer Prod Inc	Sulfonyl amide derivatives for the treatment of abnormal cell growth
RU2009143753A (ru)	2007-04-27	2011-06-10	Астразенека Аб (Se)	Производные n'-(фенил)-n-(морфолин-4-ил-пиридин-2-ил)-пиримидин-2, 4-идиамина в качестве ингибиторов ернв4 киназы для лечения пролиферативных состояний
AU2008277446A1 (en)	2007-07-16	2009-01-22	Astrazeneca Ab	Pyrimidine derivatives 934
WO2009012421A1 (en)	2007-07-17	2009-01-22	Rigel Pharmaceuticals, Inc.	Cyclic amine substituted pyrimidinediamines as pkc inhibitors
SG2014015085A (en)	2008-04-16	2014-06-27	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
CN102066340B (zh) *	2008-04-16	2014-05-14	波托拉医药品公司	作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
CN103224497A (zh)	2008-04-22	2013-07-31	波托拉医药品公司	蛋白激酶抑制剂
KR101860057B1 (ko)	2008-05-21	2018-05-21	어리어드 파마슈티칼스, 인코포레이티드	키나아제 억제제로서 포스포러스 유도체
PE20100087A1 (es)	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
KR20110025224A (ko)	2008-06-27	2011-03-09	아빌라 테라퓨틱스, 인크.	헤테로아릴 화합물 및 이의 용도
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2325175A4 (en)	2008-09-01	2012-03-21	Astellas Pharma Inc	2,4-DIAMINOPYRIMIDINVERBINDUNG
EP2331507A2 (en)	2008-09-18	2011-06-15	Astellas Pharma Inc.	Heterocyclic carboxamide compounds
UY32158A (es)	2008-10-03	2010-04-30	Astrazeneca Ab	Derivados heterociclicos y metodos de uso de los mismos
CN102272291B (zh)	2008-10-31	2018-01-16	詹森生物科技公司	人胚胎干细胞向胰腺内分泌谱系的分化
US8809538B2 (en)	2009-01-12	2014-08-19	Array Biopharma Inc.	Piperidine-containing compounds and use thereof
EP2376481B1 (en)	2009-01-13	2013-08-07	Glaxo Group Limited	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010090875A1 (en)	2009-01-21	2010-08-12	Rigel Pharmaceuticals, Inc.	Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
AR076550A1 (es) *	2009-05-06	2011-06-22	Portola Pharm Inc	Inhibidores de la janus tirosina kinasa (jak)
LT3009428T (lt) *	2009-05-08	2018-04-10	Astellas Pharma Inc.	Diamino heterociklinis karboksamido junginys
WO2010144468A1 (en)	2009-06-10	2010-12-16	Abbott Laboratories	2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko)	2009-11-30	2011-06-03	주식회사 오스코텍	피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
CA2780759A1 (en)	2009-12-01	2011-06-09	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
EP2595982B1 (en)	2010-07-21	2018-06-13	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
US8580805B2 (en)	2010-08-31	2013-11-12	Hubert Maehr	Pyrimidine carboxamide derivatives
US20130252917A1 (en)	2010-09-30	2013-09-26	Portola Pharmaceuticals, Inc.	Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine
US20130244963A1 (en)	2010-09-30	2013-09-19	Portola Pharmaceuticals, Inc.	Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
CN111471021B (zh) *	2011-04-22	2024-04-02	西格诺药品有限公司	取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
ES2658395T3 (es) *	2012-04-04	2018-03-09	Rigel Pharmaceuticals, Inc.	Inhibidores de proteína cinasa C y usos de los mismos
US9062068B2 (en) *	2012-12-04	2015-06-23	Rigel Pharmaceuticals, Inc.	Protein kinase C inhibitors and uses thereof
JP6421170B2 (ja) *	2013-03-14	2018-11-07	ライジェルファーマシューティカルズ，インコーポレイテッド	プロテインキナーゼｃ阻害剤およびその使用
CN104262328B (zh) *	2013-09-18	2016-09-07	北京韩美药品有限公司	抑制btk和/或jak3激酶活性的化合物
KR20160095159A (ko) *	2013-12-20	2016-08-10	시그날 파마소티칼 엘엘씨	치환된 디아미노피리미딜 화합물, 이의 조성물, 및 이를 사용한 치료방법
NZ715903A (en) *	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CA2970926C (en) *	2014-12-16	2023-10-24	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2975260C (en) *	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

2014
- 2014-09-03 NZ NZ715903A patent/NZ715903A/en unknown
2015
- 2015-01-29 HU HUE15743503A patent/HUE051266T2/hu unknown
- 2015-01-29 AU AU2015211036A patent/AU2015211036B2/en active Active
- 2015-01-29 KR KR1020227013115A patent/KR102760889B1/ko active Active
- 2015-01-29 TW TW104103137A patent/TWI631108B/zh active
- 2015-01-29 EA EA201691544A patent/EA031671B1/ru not_active IP Right Cessation
- 2015-01-29 CN CN202110386057.XA patent/CN113717109A/zh active Pending
- 2015-01-29 RS RS20200970A patent/RS60715B1/sr unknown
- 2015-01-29 CN CN201580016658.4A patent/CN106163523A/zh active Pending
- 2015-01-29 PE PE2016001300A patent/PE20161437A1/es not_active Application Discontinuation
- 2015-01-29 BR BR122020003206-5A patent/BR122020003206B1/pt active IP Right Grant
- 2015-01-29 SG SG11201606054SA patent/SG11201606054SA/en unknown
- 2015-01-29 WO PCT/US2015/013412 patent/WO2015116755A2/en active Application Filing
- 2015-01-29 KR KR1020167023497A patent/KR102505677B1/ko active Active
- 2015-01-29 PT PT157435033T patent/PT3099302T/pt unknown
- 2015-01-29 EA EA201792281A patent/EA036964B1/ru not_active IP Right Cessation
- 2015-01-29 MX MX2020003173A patent/MX391127B/es unknown
- 2015-01-29 DK DK15743503.3T patent/DK3099302T3/da active
- 2015-01-29 NZ NZ761068A patent/NZ761068A/en unknown
- 2015-01-29 PL PL15743503T patent/PL3099302T3/pl unknown
- 2015-01-29 MX MX2016009989A patent/MX373804B/es active IP Right Grant
- 2015-01-29 MY MYPI2016702761A patent/MY180020A/en unknown
- 2015-01-29 LT LTEP15743503.3T patent/LT3099302T/lt unknown
- 2015-01-29 SI SI201531322T patent/SI3099302T1/sl unknown
- 2015-01-29 EP EP20178344.6A patent/EP3738954A1/en active Pending
- 2015-01-29 JP JP2016549045A patent/JP2017504632A/ja active Pending
- 2015-01-29 SM SM20200430T patent/SMT202000430T1/it unknown
- 2015-01-29 CA CA2938187A patent/CA2938187C/en active Active
- 2015-01-29 BR BR112016017776A patent/BR112016017776A8/pt not_active Application Discontinuation
- 2015-01-29 CN CN202110386098.9A patent/CN113717110A/zh active Pending
- 2015-01-29 EP EP15743503.3A patent/EP3099302B1/en active Active
- 2015-01-29 ES ES15743503T patent/ES2811834T3/es active Active
- 2015-01-29 NZ NZ722412A patent/NZ722412A/en unknown
- 2015-01-29 CR CR20160346A patent/CR20160346A/es unknown
- 2015-01-29 US US14/608,314 patent/US9365524B2/en active Active
2016
- 2016-05-12 US US15/152,653 patent/US9814713B2/en active Active
- 2016-07-25 IL IL246931A patent/IL246931B/en active IP Right Grant
- 2016-07-26 PH PH12016501472A patent/PH12016501472B1/en unknown
- 2016-07-28 SA SA516371578A patent/SA516371578B1/ar unknown
- 2016-07-29 CL CL2016001927A patent/CL2016001927A1/es unknown
- 2016-07-29 MX MX2019005715A patent/MX2019005715A/es unknown
2017
- 2017-10-09 US US15/727,659 patent/US10226461B2/en active Active
2019
- 2019-02-04 US US16/266,793 patent/US10517873B2/en active Active
- 2019-04-03 JP JP2019071044A patent/JP6742466B2/ja active Active
- 2019-11-11 US US16/679,592 patent/US11241430B2/en active Active
2020
- 2020-03-26 AU AU2020202146A patent/AU2020202146B2/en active Active
- 2020-06-11 IL IL275305A patent/IL275305B/en unknown
- 2020-07-28 JP JP2020127493A patent/JP7317768B2/ja active Active
- 2020-08-07 HR HRP20201244TT patent/HRP20201244T1/hr unknown
- 2020-08-12 CY CY20201100757T patent/CY1123267T1/el unknown
2021
- 2021-12-27 US US17/562,933 patent/US20220378785A1/en not_active Abandoned
2024
- 2024-06-26 US US18/754,494 patent/US20250000860A1/en active Pending

Also Published As

Publication number	Publication date
KR102760889B1 (ko)	2025-02-03
EP3099302B1 (en)	2020-06-17
AU2020202146A1 (en)	2020-04-16
EA036964B1 (ru)	2021-01-20
MX373804B (es)	2020-03-24
CA2938187C (en)	2022-08-09
US20200078359A1 (en)	2020-03-12
US20220378785A1 (en)	2022-12-01
EA201792281A1 (ru)	2018-03-30
CN106163523A (zh)	2016-11-23
IL246931B (en)	2020-06-30
US9365524B2 (en)	2016-06-14
US10517873B2 (en)	2019-12-31
EP3738954A1 (en)	2020-11-18
JP7317768B2 (ja)	2023-07-31
MX391127B (es)	2025-03-21
NZ715903A (en)	2017-06-30
MY180020A (en)	2020-11-19
TW201615627A (zh)	2016-05-01
BR112016017776A8 (pt)	2020-06-30
CN113717110A (zh)	2021-11-30
JP2020183437A (ja)	2020-11-12
KR20220051440A (ko)	2022-04-26
US20150210650A1 (en)	2015-07-30
MX2016009989A (es)	2017-02-20
CY1123267T1 (el)	2021-12-31
ES2811834T3 (es)	2021-03-15
US20160256459A1 (en)	2016-09-08
US11241430B2 (en)	2022-02-08
IL275305B (en)	2021-12-01
WO2015116755A2 (en)	2015-08-06
US20250000860A1 (en)	2025-01-02
PE20161437A1 (es)	2017-01-07
JP6742466B2 (ja)	2020-08-19
CN113717109A (zh)	2021-11-30
BR112016017776A2 (pt)	2017-08-08
LT3099302T (lt)	2020-09-10
CL2016001927A1 (es)	2017-02-24
JP2017504632A (ja)	2017-02-09
MX2019005715A (es)	2019-08-12
HRP20201244T1 (hr)	2020-11-13
PT3099302T (pt)	2020-08-27
KR20160113269A (ko)	2016-09-28
PH12016501472A1 (en)	2016-08-22
PH12016501472B1 (en)	2019-05-31
US10226461B2 (en)	2019-03-12
EA201691544A1 (ru)	2017-01-30
US20180028534A1 (en)	2018-02-01
PL3099302T3 (pl)	2021-03-08
AU2015211036A1 (en)	2016-08-11
WO2015116755A3 (en)	2015-11-12
AU2020202146B2 (en)	2021-11-18
SA516371578B1 (ar)	2019-09-01
MX2020003173A (es)	2022-03-30
NZ761068A (en)	2023-02-24
AU2015211036B2 (en)	2020-05-21
DK3099302T3 (da)	2020-08-24
NZ722412A (en)	2022-10-28
EP3099302A2 (en)	2016-12-07
CR20160346A (es)	2016-11-23
NZ629885A (en)	2016-04-29
EA031671B1 (ru)	2019-02-28
EP3099302A4 (en)	2017-10-04
RS60715B1 (sr)	2020-09-30
TWI631108B (zh)	2018-08-01
BR122020003206B1 (pt)	2023-02-07
CA2938187A1 (en)	2015-08-06
SI3099302T1 (sl)	2020-10-30
SMT202000430T1 (it)	2020-09-10
US20190167678A1 (en)	2019-06-06
WO2015116755A8 (en)	2016-09-22
US9814713B2 (en)	2017-11-14
HUE051266T2 (hu)	2021-03-01
IL275305A (en)	2020-07-30
IL246931A0 (en)	2016-09-29
JP2019142893A (ja)	2019-08-29
KR102505677B1 (ko)	2023-03-03

Publication	Publication Date	Title
HK1247238B (zh)	2019-08-16	改造的crispr-cas9組合物和使用方法
IL275305A (en)	2020-07-30	Solid forms of 2– (tert-butylamino) –4 - ((1R, 3R, 4R) –3– hydroxy-4 – methylcyclohexylamino) –pyrimidine – 5 – carboxamide, their compositions and methods of use
IL252900A0 (en)	2017-08-31	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
IL259246A (en)	2018-07-31	Preparations containing pharmaceutical substances and methods of using them
HK1254822A1 (zh)	2019-07-26	用於減少tau表現之組合物及方法
HK1259372A1 (zh)	2019-11-29	治療化合物、其組合物及使用方法
IL277814A (en)	2020-11-30	Automatic preparations containing cyclobenzaprine hydrochloride and methods for their preparation
EP3250557A4 (en)	2018-06-20	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ZA201801214B (en)	2019-08-28	Compositions and methods for treatment of stroke and other cns disorders
HK1252057A1 (zh)	2019-05-10	新穎的使用方法和組合物
HK1258765A1 (zh)	2019-11-22	治療性化合物、組合物和它們的使用方法
EP3280406A4 (en)	2019-02-20	COMPOSITIONS AND METHODS FOR TREATING MOVEMENT DISORDERS
ZA201704927B (en)	2018-12-19	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
IL247645A0 (en)	2017-01-31	Preparations of seleno-organic compounds and methods of using them